Microvascular Therapeutics Showcases Breakthrough Ultrasound Contrast Agent, MVT-100, at the 2025 ICUS Bubble Conference

Chicago, IL – October 7th, 2025 – Microvascular Therapeutics (MVT), a clinical-stage biopharmaceutical company pioneering innovations in diagnostic imaging, announced today the presentation of new data on its lead ultrasound contrast agent, CardiSon (MVT-100), at the 39^th International Bubble Conference (ICUS 2025), held September 10–11 at the Drake Hotel in Chicago, IL.

Key Findings Presented

·       Improved Safety Profile: Preclinical studies demonstrated that MVT-100 has reduced renal retention, which may significantly lower the risk of back/flank pain and vaso-occlusive complications observed with charged microbubbles.

·       Phase II Clinical Results: In a randomized study of 32 subjects, MVT-100 showed:

o   Superior contrast enhancement with statistically significant improvements in left ventricular opacification (p < .04 to < .00001).

o   Reduced cardiac shadowing in 13 of 17 segments compared to perflutren (p < .05 to < .001).

o   Excellent tolerability across all dosing regimens.

·       Preclinical Imaging: Porcine studies confirmed that MVT-100 provides longer duration of contrast enhancement compared to perflutren.

·       Neutral Surface Chemistry & Storage Advantage: Unlike Perflutren, which requires refrigerated storage and carries an electrostatic charge, MVT-100’s neutral surface chemistry allows for room-temperature stability and broadens potential theranostic applications.

Broader Impact

“These results represent a major advance in ultrasound imaging,” said Dr. Evan Unger, President and CEO. “By eliminating charged lipids that contribute to side effects and by enabling room-temperature storage, MVT-100 could set a new standard for contrast echocardiography while opening the door to novel therapeutic applications.”

Flordeliza Villanueva, MD, Professor of Medicine, Associate Chief of Cardiology for Translational Research, Director Non-Invasive Cardiac Imaging, Director Center for Ultrasound Molecular Imaging and Therapeutics at the University of Pittsburgh / UPMC system, led the blinded echocardiographic assessment from the study. She said, “We were pleased that MVT-100 showed superior contrast enhancement and significantly less shadowing. This is a promising new contrast agent that merits further clinical development.”

Support & Collaborations

The work was supported by a Phase II SBIR grant from the National Heart, Lung, and Blood Institute (R44HL137447). Key collaborators included investigators at the University of Pittsburgh, University of Virginia, St. Luke’s Kansas City, and Banner Health/University of Arizona.

About Microvascular Therapeutics

Microvascular Therapeutics (MVT) is advancing next-generation ultrasound contrast and theranostic agents with the potential to transform cardiovascular and oncology imaging and therapy. Its lead product, MVT-100, is designed to improve the safety, performance, and accessibility of ultrasound contrast worldwide.

Media Contact

Bryan Unger

Microvascular Therapeutics

Email: b.unger@mvtpharma.com

Phone: (520) 624-6699

Disclaimer:This press release contains forward-looking statements regarding Microvascular Therapeutics’ lead ultrasound contrast agent, CardiSon (MVT-100), including its potential clinical benefits, safety profile, regulatory pathway, and commercialization prospects. These statements are based on current expectations and assumptions and are subject to significant risks and uncertainties that could cause actual results to differ materially from those anticipated. Such risks include, but are not limited to, the outcomes of ongoing and future clinical trials, regulatory review and approval processes, manufacturing scale-up, market acceptance, and the availability of financing. Microvascular Therapeutics undertakes no obligation to update or revise any forward-looking statements contained herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.